Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
12 10 2020
Historique:
entrez: 13 10 2020
pubmed: 14 10 2020
medline: 22 10 2020
Statut: epublish

Résumé

Many dental procedures produce aerosols (droplets, droplet nuclei and splatter) that harbour various pathogenic micro-organisms and may pose a risk for the spread of infections between dentist and patient. The COVID-19 pandemic has led to greater concern about this risk. To assess the effectiveness of methods used during dental treatment procedures to minimize aerosol production and reduce or neutralize contamination in aerosols. Cochrane Oral Health's Information Specialist searched the following databases on 17 September 2020: Cochrane Oral Health's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (in the Cochrane Library, 2020, Issue 8), MEDLINE Ovid (from 1946); Embase Ovid (from 1980); the WHO COVID-19 Global literature on coronavirus disease; the US National Institutes of Health Trials Registry (ClinicalTrials.gov); and the Cochrane COVID-19 Study Register. We placed no restrictions on the language or date of publication. We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) on aerosol-generating procedures (AGPs) performed by dental healthcare providers that evaluated methods to reduce contaminated aerosols in dental clinics (excluding preprocedural mouthrinses). The primary outcomes were incidence of infection in dental staff or patients, and reduction in volume and level of contaminated aerosols in the operative environment. The secondary outcomes were cost, accessibility and feasibility. Two review authors screened search results, extracted data from the included studies, assessed the risk of bias in the studies, and judged the certainty of the available evidence. We used mean differences (MDs) and 95% confidence intervals (CIs) as the effect estimate for continuous outcomes, and random-effects meta-analysis to combine data. We assessed heterogeneity. We included 16 studies with 425 participants aged 5 to 69 years. Eight studies had high risk of bias; eight had unclear risk of bias. No studies measured infection. All studies measured bacterial contamination using the surrogate outcome of colony-forming units (CFU). Two studies measured contamination per volume of air sampled at different distances from the patient's mouth, and 14 studies sampled particles on agar plates at specific distances from the patient's mouth. The results presented below should be interpreted with caution as the evidence is very low certainty due to heterogeneity, risk of bias, small sample sizes and wide confidence intervals. Moreover, we do not know the 'minimal clinically important difference' in CFU. High-volume evacuator Use of a high-volume evacuator (HVE) may reduce bacterial contamination in aerosols less than one foot (~ 30 cm) from a patient's mouth (MD -47.41, 95% CI -92.76 to -2.06; 3 RCTs, 122 participants (two studies had split-mouth design); very high heterogeneity I² = 95%), but not at longer distances (MD -1.00, -2.56 to 0.56; 1 RCT, 80 participants). One split-mouth RCT (six participants) found that HVE may not be more effective than conventional dental suction (saliva ejector or low-volume evacuator) at 40 cm (MD CFU -2.30, 95% CI -5.32 to 0.72) or 150 cm (MD -2.20, 95% CI -14.01 to 9.61). Dental isolation combination system One RCT (50 participants) found that there may be no difference in CFU between a combination system (Isolite) and a saliva ejector (low-volume evacuator) during AGPs (MD -0.31, 95% CI -0.82 to 0.20) or after AGPs (MD -0.35, -0.99 to 0.29). However, an 'n of 1' design study showed that the combination system may reduce CFU compared with rubber dam plus HVE (MD -125.20, 95% CI -174.02 to -76.38) or HVE (MD -109.30, 95% CI -153.01 to -65.59). Rubber dam One split-mouth RCT (10 participants) receiving dental treatment, found that there may be a reduction in CFU with rubber dam at one-metre (MD -16.20, 95% CI -19.36 to -13.04) and two-metre distance (MD -11.70, 95% CI -15.82 to -7.58). One RCT of 47 dental students found use of rubber dam may make no difference in CFU at the forehead (MD 0.98, 95% CI -0.73 to 2.70) and occipital region of the operator (MD 0.77, 95% CI -0.46 to 2.00). One split-mouth RCT (21 participants) found that rubber dam plus HVE may reduce CFU more than cotton roll plus HVE on the patient's chest (MD -251.00, 95% CI -267.95 to -234.05) and dental unit light (MD -12.70, 95% CI -12.85 to -12.55). Air cleaning systems One split-mouth CCT (two participants) used a local stand-alone air cleaning system (ACS), which may reduce aerosol contamination during cavity preparation (MD -66.70 CFU, 95% CI -120.15 to -13.25 per cubic metre) or ultrasonic scaling (MD -32.40, 95% CI - 51.55 to -13.25). Another CCT (50 participants) found that laminar flow in the dental clinic combined with a HEPA filter may reduce contamination approximately 76 cm from the floor (MD -483.56 CFU, 95% CI -550.02 to -417.10 per cubic feet per minute per patient) and 20 cm to 30 cm from the patient's mouth (MD -319.14 CFU, 95% CI - 385.60 to -252.68). Disinfectants ‒ antimicrobial coolants Two RCTs evaluated use of antimicrobial coolants during ultrasonic scaling. Compared with distilled water, coolant containing chlorhexidine (CHX), cinnamon extract coolant or povidone iodine may reduce CFU: CHX (MD -124.00, 95% CI -135.78 to -112.22; 20 participants), povidone iodine (MD -656.45, 95% CI -672.74 to -640.16; 40 participants), cinnamon (MD -644.55, 95% CI -668.70 to -620.40; 40 participants). CHX coolant may reduce CFU more than povidone iodine (MD -59.30, 95% CI -64.16 to -54.44; 20 participants), but not more than cinnamon extract (MD -11.90, 95% CI -35.88 to 12.08; 40 participants). We found no studies that evaluated disease transmission via aerosols in a dental setting; and no evidence about viral contamination in aerosols. All of the included studies measured bacterial contamination using colony-forming units. There appeared to be some benefit from the interventions evaluated but the available evidence is very low certainty so we are unable to draw reliable conclusions. We did not find any studies on methods such as ventilation, ionization, ozonisation, UV light and fogging. Studies are needed that measure contamination in aerosols, size distribution of aerosols and infection transmission risk for respiratory diseases such as COVID-19 in dental patients and staff.

Sections du résumé

BACKGROUND
Many dental procedures produce aerosols (droplets, droplet nuclei and splatter) that harbour various pathogenic micro-organisms and may pose a risk for the spread of infections between dentist and patient. The COVID-19 pandemic has led to greater concern about this risk.
OBJECTIVES
To assess the effectiveness of methods used during dental treatment procedures to minimize aerosol production and reduce or neutralize contamination in aerosols.
SEARCH METHODS
Cochrane Oral Health's Information Specialist searched the following databases on 17 September 2020: Cochrane Oral Health's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (in the Cochrane Library, 2020, Issue 8), MEDLINE Ovid (from 1946); Embase Ovid (from 1980); the WHO COVID-19 Global literature on coronavirus disease; the US National Institutes of Health Trials Registry (ClinicalTrials.gov); and the Cochrane COVID-19 Study Register. We placed no restrictions on the language or date of publication.
SELECTION CRITERIA
We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) on aerosol-generating procedures (AGPs) performed by dental healthcare providers that evaluated methods to reduce contaminated aerosols in dental clinics (excluding preprocedural mouthrinses). The primary outcomes were incidence of infection in dental staff or patients, and reduction in volume and level of contaminated aerosols in the operative environment. The secondary outcomes were cost, accessibility and feasibility.
DATA COLLECTION AND ANALYSIS
Two review authors screened search results, extracted data from the included studies, assessed the risk of bias in the studies, and judged the certainty of the available evidence. We used mean differences (MDs) and 95% confidence intervals (CIs) as the effect estimate for continuous outcomes, and random-effects meta-analysis to combine data. We assessed heterogeneity.
MAIN RESULTS
We included 16 studies with 425 participants aged 5 to 69 years. Eight studies had high risk of bias; eight had unclear risk of bias. No studies measured infection. All studies measured bacterial contamination using the surrogate outcome of colony-forming units (CFU). Two studies measured contamination per volume of air sampled at different distances from the patient's mouth, and 14 studies sampled particles on agar plates at specific distances from the patient's mouth. The results presented below should be interpreted with caution as the evidence is very low certainty due to heterogeneity, risk of bias, small sample sizes and wide confidence intervals. Moreover, we do not know the 'minimal clinically important difference' in CFU. High-volume evacuator Use of a high-volume evacuator (HVE) may reduce bacterial contamination in aerosols less than one foot (~ 30 cm) from a patient's mouth (MD -47.41, 95% CI -92.76 to -2.06; 3 RCTs, 122 participants (two studies had split-mouth design); very high heterogeneity I² = 95%), but not at longer distances (MD -1.00, -2.56 to 0.56; 1 RCT, 80 participants). One split-mouth RCT (six participants) found that HVE may not be more effective than conventional dental suction (saliva ejector or low-volume evacuator) at 40 cm (MD CFU -2.30, 95% CI -5.32 to 0.72) or 150 cm (MD -2.20, 95% CI -14.01 to 9.61). Dental isolation combination system One RCT (50 participants) found that there may be no difference in CFU between a combination system (Isolite) and a saliva ejector (low-volume evacuator) during AGPs (MD -0.31, 95% CI -0.82 to 0.20) or after AGPs (MD -0.35, -0.99 to 0.29). However, an 'n of 1' design study showed that the combination system may reduce CFU compared with rubber dam plus HVE (MD -125.20, 95% CI -174.02 to -76.38) or HVE (MD -109.30, 95% CI -153.01 to -65.59). Rubber dam One split-mouth RCT (10 participants) receiving dental treatment, found that there may be a reduction in CFU with rubber dam at one-metre (MD -16.20, 95% CI -19.36 to -13.04) and two-metre distance (MD -11.70, 95% CI -15.82 to -7.58). One RCT of 47 dental students found use of rubber dam may make no difference in CFU at the forehead (MD 0.98, 95% CI -0.73 to 2.70) and occipital region of the operator (MD 0.77, 95% CI -0.46 to 2.00). One split-mouth RCT (21 participants) found that rubber dam plus HVE may reduce CFU more than cotton roll plus HVE on the patient's chest (MD -251.00, 95% CI -267.95 to -234.05) and dental unit light (MD -12.70, 95% CI -12.85 to -12.55). Air cleaning systems One split-mouth CCT (two participants) used a local stand-alone air cleaning system (ACS), which may reduce aerosol contamination during cavity preparation (MD -66.70 CFU, 95% CI -120.15 to -13.25 per cubic metre) or ultrasonic scaling (MD -32.40, 95% CI - 51.55 to -13.25). Another CCT (50 participants) found that laminar flow in the dental clinic combined with a HEPA filter may reduce contamination approximately 76 cm from the floor (MD -483.56 CFU, 95% CI -550.02 to -417.10 per cubic feet per minute per patient) and 20 cm to 30 cm from the patient's mouth (MD -319.14 CFU, 95% CI - 385.60 to -252.68). Disinfectants ‒ antimicrobial coolants Two RCTs evaluated use of antimicrobial coolants during ultrasonic scaling. Compared with distilled water, coolant containing chlorhexidine (CHX), cinnamon extract coolant or povidone iodine may reduce CFU: CHX (MD -124.00, 95% CI -135.78 to -112.22; 20 participants), povidone iodine (MD -656.45, 95% CI -672.74 to -640.16; 40 participants), cinnamon (MD -644.55, 95% CI -668.70 to -620.40; 40 participants). CHX coolant may reduce CFU more than povidone iodine (MD -59.30, 95% CI -64.16 to -54.44; 20 participants), but not more than cinnamon extract (MD -11.90, 95% CI -35.88 to 12.08; 40 participants).
AUTHORS' CONCLUSIONS
We found no studies that evaluated disease transmission via aerosols in a dental setting; and no evidence about viral contamination in aerosols. All of the included studies measured bacterial contamination using colony-forming units. There appeared to be some benefit from the interventions evaluated but the available evidence is very low certainty so we are unable to draw reliable conclusions. We did not find any studies on methods such as ventilation, ionization, ozonisation, UV light and fogging. Studies are needed that measure contamination in aerosols, size distribution of aerosols and infection transmission risk for respiratory diseases such as COVID-19 in dental patients and staff.

Identifiants

pubmed: 33047816
doi: 10.1002/14651858.CD013686.pub2
pmc: PMC8164845
doi:

Substances chimiques

Aerosols 0
Disinfectants 0

Banques de données

ClinicalTrials.gov
['NCT04430387']

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013686

Informations de copyright

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Br Dent J. 1978 Aug 1;145(3):76-8
pubmed: 356863
J Periodontol. 1967 Nov-Dec;38(6):550-4
pubmed: 5234643
J Am Dent Assoc. 2004 Sep;135(9):1292-302
pubmed: 15493394
J Clin Periodontol. 2004 Jun;31(6):458-62
pubmed: 15142216
Viruses. 2019 Oct 12;11(10):
pubmed: 31614743
J Oral Maxillofac Surg. 2008 Apr;66(4):704-10
pubmed: 18355594
J Hosp Infect. 2006 Sep;64(1):76-81
pubmed: 16820249
Br Dent J. 1987 Aug 22;163(4):118-9
pubmed: 3307852
J Parenter Sci Technol. 1985 Nov-Dec;39(6):256-61
pubmed: 4093827
Occup Environ Med. 2000 Nov;57(11):721-6
pubmed: 11024194
J Hosp Infect. 2019 Oct;103(2):175-184
pubmed: 31279762
J Dent Res. 1970 Nov-Dec;49(6):Suppl:1498+
pubmed: 5274380
J Infect Dis. 2018 Jul 24;218(5):739-747
pubmed: 29878137
J Dent Res. 2020 May;99(5):481-487
pubmed: 32162995
J Hosp Infect. 2000 Dec;46(4):241-56
pubmed: 11170755
J Periodontol. 1998 Apr;69(4):434-8
pubmed: 9609373
J Oral Microbiol. 2012;4:
pubmed: 22701774
J Am Dent Assoc. 2012 Nov;143(11):1199-204
pubmed: 23115148
J Can Dent Assoc. 2004 Mar;70(3):170-4
pubmed: 15003164
J Am Dent Assoc. 2004 Apr;135(4):429-37
pubmed: 15127864
Int J Oral Sci. 2020 Mar 3;12(1):9
pubmed: 32127517
J Periodontol. 1999 Jul;70(7):793-802
pubmed: 10440642
Jikken Dobutsu. 1990 Apr;39(2):223-9
pubmed: 2163330
J Contemp Dent Pract. 2012 Sep 01;13(5):681-9
pubmed: 23250175
J Indian Soc Periodontol. 2019 May-Jun;23(3):226-233
pubmed: 31143003
J Periodontol. 1997 Jan;68(1):45-9
pubmed: 9029451
Environ Res. 2014 Oct;134:405-9
pubmed: 25218707
J Dent Res Dent Clin Dent Prospects. 2014 Summer;8(3):176-9
pubmed: 25346838
J Int Soc Prev Community Dent. 2018 Jul-Aug;8(4):327-332
pubmed: 30123765
Cochrane Database Syst Rev. 2020 Oct 12;10:CD013686
pubmed: 33047816
J Family Med Prim Care. 2020 Feb 28;9(2):1003-1008
pubmed: 32318458
J Infect Public Health. 2015 May-Jun;8(3):260-5
pubmed: 25564419
J Am Dent Assoc. 1989 Jul;119(1):141-4
pubmed: 2760346
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Environ Int. 2015 Dec;85:254-72
pubmed: 26436919
Curr Opin Dent. 1991 Aug;1(4):429-35
pubmed: 1666310
Ann Agric Environ Med. 2007;14(2):203-7
pubmed: 18247451
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
ASDC J Dent Child. 1989 Nov-Dec;56(6):442-4
pubmed: 2681303
J Dent Hyg. 2002 Summer;76(3):202-6
pubmed: 12271865
Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):1122-34
pubmed: 25581979
J Dent Res. 2020 Oct;99(11):1228-1238
pubmed: 32660314
Br Dent J. 2010 Oct 23;209(8):E14
pubmed: 20953167
J Endod. 1986 Sep;12(9):396-9
pubmed: 3463645
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013626
pubmed: 32936949
Oral Dis. 2021 Apr;27 Suppl 3:651-654
pubmed: 32401373
Compend Contin Educ Dent. 1996 Dec;17(12):1185-93; quiz 1194
pubmed: 9161132
PLoS One. 2017 May 22;12(5):e0178007
pubmed: 28531183
Infect Dis Ther. 2018 Jun;7(2):249-259
pubmed: 29633177
J Clin Diagn Res. 2016 Jul;10(7):ZC53-7
pubmed: 27630954
Nature. 2020 Apr;580(7802):175
pubmed: 32242113
J Hosp Infect. 2006 Mar;62(3):385-6
pubmed: 16337711
Gen Dent. 2001 Nov-Dec;49(6):648-52
pubmed: 12024755
J Am Dent Assoc. 2015 Jan;146(1):27-33
pubmed: 25569495
J Am Dent Assoc. 1999 Sep;130(9):1354-9
pubmed: 10492544
Br Dent J. 2021 Jan 8;:
pubmed: 33414542
J Hosp Infect. 2018 Jul;99(3):303-305
pubmed: 29551649
Environ Monit Assess. 2008 Feb;137(1-3):351-61
pubmed: 17505900
J Infect Public Health. 2017 Mar - Apr;10(2):195-200
pubmed: 27234605
J Maxillofac Oral Surg. 2014 Jun;13(2):128-32
pubmed: 24822003
BMC Infect Dis. 2019 Jan 25;19(1):88
pubmed: 30683052
J Am Dent Assoc. 1994 May;125(5):579-84
pubmed: 8195499
J Oral Maxillofac Pathol. 2016 Jan-Apr;20(1):59-65
pubmed: 27194863
Br Dent J. 2010 Jul 24;209(2):87-8
pubmed: 20651774
Cochrane Database Syst Rev. 2020 Apr 15;4:CD011621
pubmed: 32293717
J Oral Rehabil. 2021 Jan;48(1):61-72
pubmed: 32966633
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013628
pubmed: 32936947
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541
Br Dent J. 2020 Apr;228(7):503-505
pubmed: 32277203
J Dent Hyg. 1992 Sep;66(7):314-8
pubmed: 1291635
J Clin Diagn Res. 2015 Apr;9(4):ZC52-7
pubmed: 26023644
Quintessence Int. 2011 May;42(5):399-405
pubmed: 21519559
Lancet Infect Dis. 2009 May;9(5):291-300
pubmed: 19393959

Auteurs

Sumanth Kumbargere Nagraj (S)

Department of Oral Medicine and Oral Radiology, Faculty of Dentistry, Melaka-Manipal Medical College, Manipal Academy of Higher Education (MAHE), Melaka, Malaysia.

Prashanti Eachempati (P)

Department of Prosthodontics, Faculty of Dentistry, Melaka-Manipal Medical College, Manipal Academy of Higher Education (MAHE), Melaka, Malaysia.

Martha Paisi (M)

Peninsula Dental Social Enterprise, Peninsula Dental School, University of Plymouth, Plymouth, UK.

Mona Nasser (M)

Peninsula Dental School, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.

Gowri Sivaramakrishnan (G)

Dental Training Department, Ministry of Health, Manama, Bahrain.

Jos H Verbeek (JH)

Cochrane Work, Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH